IPC will use the information you provide on this form to send you information about psoriasis. You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by emailing info@psoriasiscouncil.org.
By clicking the subscribe button, you agree that we may process your information in accordance with our privacy statement. We use Mailchimp and Memberclicks as our marketing automation platforms and you acknowledge the information you provide will be transferred to those platforms for processing in accordance with their privacy policy and terms.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
